Equity Profile

ABT

Abbott Laboratories

Health CareHealth Care Equipment$158.2B

Jul16Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Abbott Laboratories (ABT) is a global health care company that develops and manufactures a wide range of medical devices, diagnostics, and nutritional products. With a market cap of $158 billion, Abbott plays a crucial role in the health care sector, particularly in areas like diabetes care and cardiovascular health.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and is closely watched by investors.

$1.28

Revenue

Total revenue shows the company's ability to generate sales and is critical for assessing growth.

$12.5B

Wall Street expectations, options signals, track record, and call prep available with Pro.

ABT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+1.05%

Avg Stock Reaction

-3.34%

Last Quarter Recap

In Q1-2026, Abbott reported an EPS of $1.15, slightly beating expectations. However, the stock dropped 6% the following day, indicating investor caution despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Abbott to report solid earnings this quarter, with a consensus EPS of $1.28. However, the stock's recent performance suggests that investors may be cautious about potential future growth.

Bull Case

If Abbott exceeds EPS expectations and shows strong revenue growth, it could signal robust demand for its products, boosting investor confidence.

Bear Case

Conversely, if Abbott fails to meet expectations or provides weak guidance, it could lead to further stock declines, especially given the recent negative reactions to earnings reports.

Key Metrics to Watch

EPS

$1.28

Earnings per share is a key indicator of profitability and is closely watched by investors.

Revenue

$12.5B

Total revenue shows the company's ability to generate sales and is critical for assessing growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Abbott's EPS exceed the consensus estimate of $1.28?

A strong EPS could reassure investors about the company's profitability and growth potential.

What guidance will Abbott provide for future revenue growth?

Future revenue guidance will be critical for assessing the company's outlook and could significantly impact stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Abbott's growth potential in emerging markets, which could drive higher-than-expected revenue.

Supporting Evidence

Recent product launches in diabetes care have shown strong initial demand, which may not be fully reflected in consensus estimates.

The options market is pricing in a larger move than historical averages, indicating potential for a significant surprise.

Key Risk

If Abbott's revenue growth exceeds $12.7B, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Abbott's ability to sustain growth in a competitive health care environment.

Bull Confirmed If

An EPS of $1.30 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $1.26 would confirm the bear case, suggesting weakening performance.

Pre-Earnings Positioning

Options Market

Implied Move

±8.67%

Historical Avg

±4.6%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±8.7% while ABT has averaged ±4.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

26.1%

Calls (760K)P/C Ratio: 0.51Puts (2.8M)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Abbott beats expectations, history suggests the stock could rise by around 4.62%, confirming positive investor sentiment.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may remain flat or see a slight decline.

Miss

If Abbott misses expectations, history indicates a potential drop of around 3.34%, reflecting investor disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·3 sells

Members

House only

Est. Notional

$6,006.00–$90,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in the diabetes care segment.
2Management's commentary on market conditions and competitive pressures.
3Details on revenue growth in international markets.
4Insights into supply chain stability and its impact on production.
5Any changes in guidance for the upcoming quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Fastenal Company

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and is closely watched by investors.

$1.28

Revenue

Total revenue shows the company's ability to generate sales and is critical for assessing growth.

$12.5B

Wall Street expectations, options signals, track record, and call prep available with Pro.

ABT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

100%

Avg EPS Surprise

+1.05%

Avg Stock Reaction

-3.34%

Last Quarter Recap

In Q1-2026, Abbott reported an EPS of $1.15, slightly beating expectations. However, the stock dropped 6% the following day, indicating investor caution despite the earnings beat.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Abbott exceeds EPS expectations and shows strong revenue growth, it could signal robust demand for its products, boosting investor confidence.

Bear Case

Conversely, if Abbott fails to meet expectations or provides weak guidance, it could lead to further stock declines, especially given the recent negative reactions to earnings reports.

Key Metrics to Watch

EPS

$1.28

Earnings per share is a key indicator of profitability and is closely watched by investors.

Revenue

$12.5B

Total revenue shows the company's ability to generate sales and is critical for assessing growth.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Abbott's EPS exceed the consensus estimate of $1.28?

A strong EPS could reassure investors about the company's profitability and growth potential.

What guidance will Abbott provide for future revenue growth?

Future revenue guidance will be critical for assessing the company's outlook and could significantly impact stock performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Abbott's growth potential in emerging markets, which could drive higher-than-expected revenue.

Supporting Evidence

Recent product launches in diabetes care have shown strong initial demand, which may not be fully reflected in consensus estimates.

The options market is pricing in a larger move than historical averages, indicating potential for a significant surprise.

Key Risk

If Abbott's revenue growth exceeds $12.7B, it could challenge the current cautious outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating Abbott's ability to sustain growth in a competitive health care environment.

Bull Confirmed If

An EPS of $1.30 or higher would confirm the bull case, indicating strong profitability.

Bear Confirmed If

An EPS below $1.26 would confirm the bear case, suggesting weakening performance.

Pre-Earnings Positioning

Options Market

Implied Move

±8.67%

Historical Avg

±4.6%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±8.7% while ABT has averaged ±4.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

26.1%

Calls (760K)P/C Ratio: 0.51Puts (2.8M)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Abbott beats expectations, history suggests the stock could rise by around 4.62%, confirming positive investor sentiment.

In-Line / Cautious

If results are in line with expectations but management is cautious, the stock may remain flat or see a slight decline.

Miss

If Abbott misses expectations, history indicates a potential drop of around 3.34%, reflecting investor disappointment.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

2 buys·3 sells

Members

House only

Est. Notional

$6,006.00–$90,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
2

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in the diabetes care segment.
2Management's commentary on market conditions and competitive pressures.
3Details on revenue growth in international markets.
4Insights into supply chain stability and its impact on production.
5Any changes in guidance for the upcoming quarters.